138 related articles for article (PubMed ID: 32281132)
1. Computerised scoring protocol for identification and quantification of different immune cell populations in breast tumour regions by the use of QuPath software.
Berben L; Wildiers H; Marcelis L; Antoranz A; Bosisio F; Hatse S; Floris G
Histopathology; 2020 Jul; 77(1):79-91. PubMed ID: 32281132
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.
Althobiti M; Aleskandarany MA; Joseph C; Toss M; Mongan N; Diez-Rodriguez M; Nolan CC; Ashankyty I; Ellis IO; Green AR; Rakha EA
Histopathology; 2018 Dec; 73(6):887-896. PubMed ID: 29947077
[TBL] [Abstract][Full Text] [Related]
3. Computerised counting of tumour infiltrating lymphocytes in 90 breast cancer specimens.
Marsigliante S; Biscozzo L; Marra A; Nicolardi G; Leo G; Lobreglio GB; Storelli C
Cancer Lett; 1999 May; 139(1):33-41. PubMed ID: 10408906
[TBL] [Abstract][Full Text] [Related]
4. Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis.
Loughrey MB; Bankhead P; Coleman HG; Hagan RS; Craig S; McCorry AMB; Gray RT; McQuaid S; Dunne PD; Hamilton PW; James JA; Salto-Tellez M
Histopathology; 2018 Aug; 73(2):327-338. PubMed ID: 29575153
[TBL] [Abstract][Full Text] [Related]
5. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
[TBL] [Abstract][Full Text] [Related]
6. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
[TBL] [Abstract][Full Text] [Related]
7. Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AciCC) of the Salivary Glands.
Hiss S; Eckstein M; Segschneider P; Mantsopoulos K; Iro H; Hartmann A; Agaimy A; Haller F; Mueller SK
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33669038
[TBL] [Abstract][Full Text] [Related]
8. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
Beguinot M; Dauplat MM; Kwiatkowski F; Lebouedec G; Tixier L; Pomel C; Penault-Llorca F; Radosevic-Robin N
BMC Cancer; 2018 Feb; 18(1):129. PubMed ID: 29394917
[TBL] [Abstract][Full Text] [Related]
9. Computer-assisted stereology and automated image analysis for quantification of tumor infiltrating lymphocytes in colon cancer.
Eriksen AC; Andersen JB; Kristensson M; dePont Christensen R; Hansen TF; Kjær-Frifeldt S; Sørensen FB
Diagn Pathol; 2017 Aug; 12(1):65. PubMed ID: 28851404
[TBL] [Abstract][Full Text] [Related]
10. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
11. Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer.
Verma R; Hanby AM; Horgan K; Verghese ET; Volpato M; Carter CR; Hughes TA
Breast Cancer Res Treat; 2020 Aug; 183(1):49-59. PubMed ID: 32577938
[TBL] [Abstract][Full Text] [Related]
12. Quantifying tumour-infiltrating lymphocyte subsets: a practical immuno-histochemical method.
Loughlin PM; Cooke TG; George WD; Gray AJ; Stott DI; Going JJ
J Immunol Methods; 2007 Apr; 321(1-2):32-40. PubMed ID: 17324439
[TBL] [Abstract][Full Text] [Related]
13. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
14. Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer.
Miyan M; Schmidt-Mende J; Kiessling R; Poschke I; de Boniface J
J Transl Med; 2016 Jul; 14(1):227. PubMed ID: 27473163
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?
Koletsa T; Kotoula V; Koliou GA; Manousou K; Chrisafi S; Zagouri F; Sotiropoulou M; Pentheroudakis G; Papoudou-Bai A; Christodoulou C; Xepapadakis G; Zografos G; Petraki K; Pazarli E; Koutras A; Kourea HP; Bafaloukos D; Chatzopoulos K; Iliadis A; Markopoulos C; Venizelos V; Arnogiannaki N; Kalogeras KT; Kostopoulos I; Gogas H; Fountzilas G
Cancer Immunol Immunother; 2020 Aug; 69(8):1549-1564. PubMed ID: 32303794
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.
De Angelis C; Nagi C; Hoyt CC; Liu L; Roman K; Wang C; Zheng Y; Veeraraghavan J; Sethunath V; Nuciforo P; Wang T; Tsimelzon A; Mao S; Hilsenbeck SG; Trivedi MV; Cataldo ML; Pavlick A; Wolff AC; Weigelt B; Reis-Filho JS; Prat A; Gutierrez C; Osborne CK; Rimawi MF; Schiff R
Clin Cancer Res; 2020 Feb; 26(3):738-745. PubMed ID: 31653641
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ.
Miligy I; Mohan P; Gaber A; Aleskandarany MA; Nolan CC; Diez-Rodriguez M; Mukherjee A; Chapman C; Ellis IO; Green AR; Rakha EA
Histopathology; 2017 Aug; 71(2):258-268. PubMed ID: 28326600
[TBL] [Abstract][Full Text] [Related]
18. Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients.
Ogiya R; Niikura N; Kumaki N; Bianchini G; Kitano S; Iwamoto T; Hayashi N; Yokoyama K; Oshitanai R; Terao M; Morioka T; Tsuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
Cancer Sci; 2016 Dec; 107(12):1730-1735. PubMed ID: 27727484
[TBL] [Abstract][Full Text] [Related]
19. CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis.
Ziai J; Gilbert HN; Foreman O; Eastham-Anderson J; Chu F; Huseni M; Kim JM
PLoS One; 2018; 13(1):e0190158. PubMed ID: 29320521
[TBL] [Abstract][Full Text] [Related]
20. Distribution of CXCR4 and tumour-infiltrating lymphocytes in breast cancer subtypes; their relationship with each other, axillary lymph node involvement, and other prognostic indicators.
Pehlivan FS; Sivrikoz ON; Dag F; Kececi SD; Sanal SM
Pol J Pathol; 2018; 69(4):335-341. PubMed ID: 30786682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
